VERA - Company ID 0001831828
The table below shows Vera Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$106.50M | -$54.41M | -$33.83M | -$26.29M | -$8.98M | -$4.12M |
| Capital expenditure | $23.00K | $187.00K | $0.00 | $0.00 | $18.00K | $0.00 |
| Investing cash flow | -$137.82M | $15.32M | -$219.29M | $12.23M | -$39.45M | $0.00 |
| Dividends paid | - | - | - |
Vera Therapeutics, Inc. reported operating cash flow of -$241.10M for fiscal year 2025. That is down 79.0% from -$134.68M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$34.81M (FY 2020) to -$241.10M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $3.94M | $1.53M | $276.54M | $107.98M | $80.27M | -$28.00K |